CD8A and rectal cancer: Based on these findings, we explored the impact of nRCT on the frequency of rectal cancer-infiltrating CD3+ T lymphocytes, total CD8+ T lymphocytes, and GrzB-expressing CD8+ T cells in matched pre-nRCT and post-nRCT tumor samples of 18 patients.